The new codes are for describing the infusion of tixagevimab and cilgavimab monoclonal antibody (code XW023X7), and the infusion of other new technology monoclonal antibody (code XW023Y7).
Search the full ICD-10 catalog by:
The ICD-10-CM is a catalog of diagnosis codes used by medical professionals for medical coding and reporting in health care settings. The Centers for Medicare and Medicaid Services (CMS) maintain the catalog in the U.S. releasing yearly updates.
ICD-10-CM Code for Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter T45. 1X5A.
1 for Encounter for antineoplastic chemotherapy and immunotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
ICD-10 Code ICD-10 Description Assign when immunodeficiency is due to: D84. 821 Immunodeficiency due to drugs Medications that interfere with the immune system. These medications include immunosuppressants, corticosteroids, and chemotherapy.
Z5111 - ICD 10 Diagnosis Code - Encounter for antineoplastic chemotherapy - Market Size, Prevalence, Incidence, Quality Outcomes, Top Hospitals & Physicians.
Assign code V58. 11, Encounter for antineoplastic chemotherapy, as the principal diagnosis if a patient is admitted solely for chemotherapy administration.
ICD-10 Code for Other long term (current) drug therapy- Z79. 899- Codify by AAPC.
Personal history of immunosuppression therapy Z92. 25 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z92. 25 became effective on October 1, 2021.
1X5 for Adverse effect of antineoplastic and immunosuppressive drugs is a medical classification as listed by WHO under the range - Injury, poisoning and certain other consequences of external causes .
People with immunodeficiency or autoimmune disease are considered immunocompromised, but other factors can also cause someone to be immunocompromised, such as cancer, cancer treatments, metabolic disorders or advanced age, according to The University of Texas MD Anderson Cancer Center.
C61: Malignant neoplasm of prostate.
Encounter for antineoplastic chemotherapy 11 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z51. 11 became effective on October 1, 2021. This is the American ICD-10-CM version of Z51.
Antineoplastic drugs are medications used to treat cancer. Other names for antineoplastic drugs are anticancer, chemotherapy, chemo, cytotoxic, or hazardous drugs.
T61 Toxic effect of noxious substances eaten as seafood. T62 Toxic effect of other noxious substances eaten as food. T63 Toxic effect of contact with venomous animals and plants. T64 Toxic effect of aflatoxin and other mycotoxin food contaminants.
In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere.". Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code.
Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances. Code First. , for adverse effects, the nature of the adverse effect, such as:
In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere.". Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code.
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
There are also codes Z85.6, Personal history of leukemia, and Z85.79, Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues. If the documentation is unclear as to whether the leukemia has achieved remission, the provider should be queried.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion '), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.
Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms , such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary ( metastatic) sites should also be determined.
Code C80.0, Disseminated malignant neoplasm, unspecified, is for use only in those cases where the patient has advanced metastatic disease and no known primary or secondary sites are specified. It should not be used in place of assigning codes for the primary site and all known secondary sites.
When a pregnant woman has a malignant neoplasm, a code from subcategory O9A.1 -, malignant neoplasm complicating pregnancy, childbirth, and the puerperium, should be sequenced first, followed by the appropriate code from Chapter 2 to indicate the type of neoplasm. Encounter for complication associated with a neoplasm.
Code C80.1, Malignant ( primary) neoplasm, unspecified, equates to Cancer, unspecified. This code should only be used when no determination can be made as to the primary site of a malignancy. This code should rarely be used in the inpatient setting.
441 Disorders of liver except malignancy, cirrhosis or alcoholic hepatitis with mcc. 442 Disorders of liver except malignancy, cirrhosis or alcoholic hepatitis with cc. 443 Disorders of liver except malignancy, cirrhosis or alcoholic hepatitis without cc/mcc. 791 Prematurity with major problems.
K71.6 Toxic liver disease with hepatitis, not elsewhere classified. K71.7 Toxic liver disease with fibrosis and cirrhosis of liver. K71.8 Toxic liver disease with other disorders of liver. K71.9 Toxic liver disease, unspecified. K72 Hepatic failure, not elsewhere classified.